
QED Therapeutics Stock
Precision medicine for FGFR-driven disorders
Sign up today and learn more about QED Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About QED Therapeutics Stock
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Investors
BridgeBio
Funding History
January 2018 | $65.0M |
---|
Management
President
Neil Kumar
Chief Revenue Officer
Curtis Scribner
Press
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase